GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
BOTHELL, Wash., Jan. 03, 2018 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast its presentation at the upcoming J.P. Morgan Healthcare Conference at 4:00 p.m. PT (7:00 p.m. ET) on Monday, January 8, 2018 in San Francisco, CA. The presentation will feature a corporate overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.
A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for at least 30 days after the live event concludes.
Presentation Link: https://jpmorgan.metameetings.net/events/healthcare18/sessions/13306-alder-biopharmaceuticals-inc/webcast
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company committed to transforming the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions. Leveraging its pioneering monoclonal antibody technologies, Alder discovers and develops novel therapeutic antibodies designed to deliver highly differentiated, best-in-class clinical profiles. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody administered quarterly via infusion that allows for 100% of the dose available to selectively and potently inhibit the calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contacts:
Ashley Cadle
TogoRun
(310) 463-0143
[email protected]
Investor Relations Contact:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
[email protected]
